Uncategorized

Barclays Maintains Overweight on Voya Financial, Raises Price Target to $80

Barclays analyst Jeremy Campbell maintains Voya Financial (NYSE:VOYA) with a Overweight and raises the price target from $77 to $80.

byBenzinga Newsdesk

May 12, 2021

1 minute read

Barclays analyst Jeremy Campbell maintains Voya Financial (NYSE:VOYA) with a Overweight and raises the price target from $77 to $80.

Delta 9 Claims To Be Launching Canada’s First Mobile Cannabis Store, Opening 35th Cannabis Retail Store

By Vuk Zdinjak

Today, 3:11 AM

DELTA 9 CANNABIS INC. (OTCQX: DLTNF) (TSX:DN), announced the launch of its first mobile cannabis store, and the grand opening of its thirty-fifth Delta 9 Cannabis retail store.

DLTNF

Dividends

TriMas’s Ex-Dividend Date Is Wednesday, Here’s What You Need To Know

By Benzinga Insights

Today, 3:11 AM

Tuesday marks the last chance for investors to receive the next dividend payout from TriMas (NASDAQ:TRS).

TRS

News

Environmental Impact Acquisition Corp., GreenLight Biosciences Report Expansion Of Its PIPE Financing To $124M In Gross Proceeds

By Benzinga Newsdesk

Today, 3:11 AM

GreenLight Biosciences Inc., an RNA-focused biotech ("GreenLight"), and Environmental Impact Acquisition Corp. (NASDAQ:ENVI) today announced an expansion of its PIPE financing to an aggregate $124 million in

ENVI

Events
News

Neoleukin Therapeutics Reports Will Present At Canaccord’s Horizons In Oncology Conference Thursday, Apr. 14, 2022 At 12 p.m. EDT

By Benzinga Newsdesk

Today, 3:11 AM

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that

NLTX

Barclays Maintains Overweight on Voya Financial, Raises Price Target to $80

Related Posts

Delta 9 Claims To Be Launching Canada’s First Mobile Cannabis Store, Opening 35th Cannabis Retail Store

TriMas’s Ex-Dividend Date Is Wednesday, Here’s What You Need To Know

Environmental Impact Acquisition Corp., GreenLight Biosciences Report Expansion Of Its PIPE Financing To $124M In Gross Proceeds

Neoleukin Therapeutics Reports Will Present At Canaccord’s Horizons In Oncology Conference Thursday, Apr. 14, 2022 At 12 p.m. EDT